← Eichor
Study identifier: NCT07458880 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Triple Antihypertensive Medication After Intracerebral Hemorrhage for Blood Pressure Control

Condition: Intracerebral Hemorrhage  ·  Sponsor: The University of Hong Kong

PhaseNA
Planned participants140
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Intracerebral hemorrhage (ICH) is the second most common form of stroke, with an incidence of around 3000 cases per year in Hong Kong. Although it only accounts for around 20-30% of all strokes, ICH is the most severe form of stroke, contributing to 50% of all stroke mortality and the greatest disability burden in stroke. For those who survive their ICH, they are at high risk of ICH recurrence, stroke, cardiovascular event and death. Hence, reducing these risks after ICH is a top priority to lessen the disease's healthcare and social burden. Hypertension is the main driver for ICH, and achieving blood pressure (BP) control significantly reduces the risk of recurrent ICH, stroke and cardiovascular events. However, only 50% of ICH survivors achieved BP control after ICH. This is because ICH patients represent a unique hypertensive population with more difficult-to-control BPs, with many requiring ≥3 antihypertensive medications. Many reasons contribute to uncontrolled hypertension, but inadequate prescription of medication is the most actionable cause. The notion of an upfront prescription of a triple antihypertensive regimen (triple pill) soon after ICH could consequent better BP control, but there are concerns of excessive lowering of BP, particularly in older patients, which has been associated with increased mortality. This approach may also not be suitable for ICH patients with cerebral amyloid angiopathy where the elevated admission BP may be due to acute hypertensive re…

This description comes directly from the study's public registry record.

Talk to the study team

Kay Cheong TEO  ·  +852 2255 5318  ·  kcteo@hku.hk

Always discuss trial participation with your own doctor first.

Locations (4)

Princess Margaret HospitalHong Kong, Hong Kong, Hong KongNot Yet Recruiting
Queen Mary HospitalHong Kong, Hong Kong, Hong KongRecruiting
Ruttonjee HospitalHong Kong, Hong Kong, Hong KongNot Yet Recruiting
Yan Chai HospitalHong Kong, Hong Kong, Hong KongNot Yet Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07458880